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Sequential release of milk protein–derived bioactive peptides in
the jejunum in healthy humans1–4
Rachel Boutrou, Claire Gaudichon, Didier Dupont, Julien Jardin, Gheorghe Airinei, Agnès Marsset-Baglieri,
Robert Benamouzig, Daniel Tomé, and Joëlle Leonil
ABSTRACT
Background: The digestive hydrolysis of dietary proteins leads to the
release of peptides in the intestinal tract, where they may exert a variety
of functions, but their characterization and quantification are difficult.
Objectives: We aimed to characterize and determine kinetics of the
formation of peptides present in the jejunum of humans who in-
gested casein or whey proteins by using mass spectrometry and to
look for and quantify bioactive peptides.
Design: Subjects were equipped with a double-lumen nasogastric
tube that migrated to the proximal jejunum. A sample collection
was performed for 6 h after the ingestion of 30 g 15N-labeled casein
(n = 7) or whey proteins (WPs; n = 6). Nitrogen flow rates were
measured, and peptides were identified by using mass spectrometry.
Results: After casein ingestion, medium-size peptides (750–1050
kDa) were released during 6 h, whereas larger peptides (1050–1800
kDa) were released from WPs in the first 3 h. A total of 356 and 146
peptides were detected and sequenced in the jejunum after casein
and WP ingestion, respectively. b-casein was the most important
precursor of peptides, including bioactive peptides with various
activities. The amounts of b-casomorphins (b-casein 57–, 58–,
59–, and 60–66) and b-casein 108–113 released on the postprandial
window were sufficient to elicit the biological action of these pep-
tides (ie, opioid and antihypertensive, respectively).
Conclusions: Clear evidence is shown of the presence of bioactive
peptides in the jejunum of healthy humans who ingested casein. Our
findings raise the question about the physiologic conditions under
which these peptides can express their bioactivity in humans. This
trial was registered at clinicaltrials.gov as NCT00862329. Am J
Clin Nutr 2013;97:1314–23.
INTRODUCTION
Protein digestion is a complex process that involves dynamic
movements and exchanges of proteins, peptides, amino acids,
urea, and ammonia between the gut lumen and systemic pools.
After their ingestion, dietary proteins are mixed with almost an
equal quantity of endogenous protein voided into the digestive
tract (1). This protein material is hydrolyzed by luminal gastric
and pancreatic enzymes and epithelial brush border membrane
peptidases into a complex mixture of oligopeptides, dipeptides,
tripeptides, and free amino acids that transit and are progressively
absorbed along the small intestine. Different studies have sug-
gested that bioactive peptides released from dietary protein
during digestion could exert metabolic and physiologic actions
by acting on specific targets at the digestive level or after
absorption (2–5), and some studies have particularly identified
potential bioactive peptides in the sequence of milk proteins
(6).
In vitro studies have been performed to determine peptides
released throughout simulated gastrointestinal digestion. How-
ever, peptides produced by in vitro digestion can differ from those
generated in vivo because the environmental conditions of in vivo
digestion can hardly be reproduced such as the enzyme:substrate
ratio, reaction time, and pH, which all control digestion variables
and change through in vivo digestion (7). In addition, in vivo
digestion can be considered dynamic phenomena that result from
a continuous delivery of gastric effluents in the small intestine,
with the intestinal absorption of some nutrients in the upper part
of the tract while others continue to the distal part. To understand
the metabolic and physiologic consequences of the interaction
between dietary proteins and the gastrointestinal tract, the ef-
fective in vivo release of peptides has to be established. Only
scarce in vivo studies have been undertaken to identify peptides
released by digestion in animals (8, 9), human (10, 11), and both
(12, 13), despite promoting outcomes of this topic.
Accordingly, this study aimed to characterize digestion products
and, particularly, peptides released in the jejunum after ingestion of
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either milk casein or whey proteins (WPs)5 in healthy human
subjects. We used a gastrointestinal tube technique to collect ef-
fluents as well as mass spectrometry (MS) to extensively iden-
tify and quantify milk protein–derived peptides.
SUBJECTS AND METHODS
Production of milk proteins
Milk proteins were intrinsically labeled with 15N, purified, and
prepared as previously described (14). Briefly the milk was
defatted and microfiltered on a 1.4-mm membrane. The perme-
ate was concentrated and microfiltered on a 0.1-mm membrane,
which allowed the separation of micellar caseins in the retentate
and WPs in the permeate; the latter was concentrated further by
ultrafiltration on a 5-kDa membrane. Each fraction was lyoph-
ilized and analyzed for microbiological quality.
Participants and experimental design
All participants were certified as being in good health after
a thorough examination performed by the medical staff of the
Human Nutrition Research Centre of Avicenne Hospital and
routine biochemical tests. Eligibility criteria were as follows:
negative serology for HIV and hepatitis B and C; the absence of
any pathology; the absence of an allergy to dairy proteins; preg-
nancy or absence of contraception for women; BMI (in kg/m2)
,30; and age 18–40 y. The purpose and potential risks of the
study as well as constraints because of the obligatory dietary
standardization period were fully explained to subjects. Written
informed consent was obtained from all participants, and the
protocol was approved by the Institutional Review Board of Saint-
Germain-en-Laye Hospital. This trial was registered at clin-
icaltrials.gov as NCT00862329 (SURPROL).
The study was single-blinded trial and was conducted by using
a 2-arm parallel design. Twenty-six subjects were initially recruited
fromMarch 2008 to June 2010. The recruitment was stoppedwhen 8
exploitable kinetics were obtained in each group. Regarding pre-
vious experiments on digestive kinetics (15–17), this size sample
was considered to be sufficient to discriminate between groups.
Because of various difficulties with the tolerance of the nasojejunal
tube (painful, vomiting, and nonmigration through the pylorus), the
study was finally performed in 16 subjects [10 men and 6 women;
BMI (mean6 SD): 28.36 1.8; age: 306 6 y] (Table 1). Subjects
were alternately allocated to either a casein or whey group to avoid
any random effect as a result of the season (such as the usual diet of
the subject). However, during the last phase of the study, sex, age,
and BMI were used as criteria to homogenize groups.
Standardization diet and experimental meal
The diet of subjects was standardized during 9 d to achieve
a protein intake of 1.4 g $ kg21 $ d21, which corresponded to the
average protein intake of the French population; see Table S1
under “Supplemental data” in the online issue for an example of
the dietary notebook. The daily protein intake of subjects included
a habituation to their protein supplement, which comprised 30 g
casein or WPs (Ingredia), 27.5 g maltodextrine (Roquette), and
2.5 g orange flavor. At the beginning of the standardization, each
subject was given 7 shakers that contained the supplement powder
for self-administration after dissolution in 500 mL H2O. The ex-
perimental meal was the same as the daily supplement, but pro-
teins were intrinsically labeled with 15N. Subjects were not aware
of the nature of the protein they received.
Jejunal-sample collection and preparation
On the eighth day, subjects came to the Human Nutrition Re-
search Centre of Avicenne Hospital to achieve a digestive explo-
ration. Subjects were equipped with a double-lumen nasogastric
tube that migrated to the proximal jejunum, as previously described
(17). The location of the sampling site was controlled by using
radiography. On the ninth day, after subjects fasted overnight,
a solution of polyethylene glycol 4000, which was used as
a nonabsorbable marker, was infused through the intestinal tube.
A basal collection of jejunal effluents was performed during
0.5 h, after which subjects were asked to ingest their test meal as
previously described. Sample collection was performed for 6 h
after the ingestion of the test meal. Jejunal effluents were con-
tinuously collected on ice and pooled every 30 min. The effluents
were freeze-dried until analysis. The concentration of poly-
ethylene glycol 4000 in digesta samples was determined by using
a turbidimetric method (18) to determine the liquid flow rate. The
total nitrogen in the digesta was determined by using an elemental
nitrogen analyzer (Euro Elemental Analyzer 3000; EuroVector)
with atropina as a standard. The 15N:14N isotope ratio was de-
termined by using isotope-ratio MS (Optima; Fisons Instruments).
The atom percent excess (APE) of samples were calculated by
subtracting the baseline value from the atom percentage determined
at each time point. The nitrogen flow rate was calculated as follows:
TotalN ðmmolÞ ¼ flow ðmLÞ3N ð%Þ3DM ð%ÞO 14 ð1Þ
where flow is the liquid flow rate, N is the age 18–40 y nitrogen in
the sample expressed as percentage, DM is the dry matter, and
14 is the nitrogen molar mass. The dietary nitrogen flow rate was
calculated as follows:
Dietary N ðmmolÞ ¼ TotalN ðmmolÞ3APE sample
OAPEmeal
ð2Þ
where APE sample and APE meal are the 15N enrichments in
the digesta and meal, respectively. For additional protein and
peptide analysis, 0.1 g freeze-dried samples were solubilized
at 0.1 g/mL in 50 mmol tris-HCl buffer/L (pH 8.0) and 8 mol
urea/L, which were hardly stirred and incubated at 408C for
TABLE 1
Characteristics of subjects
Casein (n = 8) Whey protein (n = 8)
Sex (no. M, no. F) 5, 3 5, 3
Age (y) 32 6 61 28 6 7
Weight (kg) 85 6 8 86 6 7
BMI (kg/m2) 28.5 6 2.1 28.1 6 1.3
1Mean 6 SD (all such values).
5Abbreviations used: ACE, angiotensin-converting enzyme; APE, atom
percent excess; BSA, bovine serum albumin; IC50, half maximal inhibitory
concentration; MS, mass spectrometry; MS/MS, tandem mass spectrometry;
TFA, trifluoroacetic acid; WP, whey protein; XIC, extracted ion chromatogram.
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1 h to dissolve the freeze-dried digest. The samples were cen-
trifuged for 10 min at 10,0003 g. A total of 300 mL supernatant
fluid was diluted in 900 mL 50 mmol Tris-HCl buffer/L (pH 8.0)
to a 25-g/L final concentration and filtered through a 0.45-mm
filter (Minisart). Samples were frozen at 2208C until analysis.
Identification of peptides by using tandem
mass spectrometry
All mass spectra were performed by using a hybrid quadrupole
time-of-flight mass spectrometer (QStar XL; MDS Sciex). The
instrument was calibrated with a multipoint calibration by using
fragment ions that resulted from the collision-induced decom-
position of a peptide from b-casein (193–209) (NeoMPS SA).
After a 1:200 dilution in 0.1% trifluoroacetic acid (TFA) (Pierce,
Touzart et Matignon), the peptide fraction (10 mL) was trapped
onto a C18 PepMap 100 microprecolumn cartridge (300-mm inner
diameter3 5 mm; Dionex) before the separation of peptides onto
a C18 PepMap 100 column (75-mm inner diameter 3 150 mm;
Dionex). The separation started with 5% solvent B for 5 min, and
a linear gradient from 5% to 70% of solvent B for 65 min was
performed at a flow rate of 200 nL/min. Solvent A contained
2% acetonitrile, 0.08% formic acid, and 0.01% TFA in liquid
chromatography–grade water; and solvent B contained 95%
acetonitrile, 0.08% formic acid, and 0.01% TFA in liquid chro-
matography–grade water. Online separated peptides were ana-
lyzed by using electrospray ionisation on a quadrupole time-of-
flight mass spectrometer in positive-ion mode. An optimized
voltage of 3.2 kV was applied to the nanoelectrospray ion source
(Proxeon Biosystems A/S). MS and tandem mass spectrometry
(MS/MS) data were acquired in continuum mode. Data-direct
analysis was used to perform MS/MS analysis on 1+- to 4+-
charged precursor ions. Precursor selection was based on ion
intensity and charge state, and if the precursors had been pre-
viously selected for fragmentation, they were excluded for the
rest of the analysis. Spectra were collected in the selected mass
range from 400 to 1500 m/z for MS spectra and from 60 to
2000 m/z for MS/MS. The mass spectrometer was operated in
data-dependent mode, which automatically switched between
MS and MS/MS acquisition with Analyst QS 1.1 software
(Applied Biosystems) when the intensity of the ions was
.10 counts/s. To identify peptides, all data (MS and MS/MS)
were submitted to MASCOT v.2.2 software (Matrix Science).
The search was performed against a homemade database that
deals with major milk proteins that represent a portion of the
Swissprot database (http://www.uniprot.org); consequently, en-
dogenous proteins were not identified in the current study. No
specific enzyme cleavage was used, and the peptide mass toler-
ance was set to 0.2 Da for MS and 0.15 Da for MS/MS. For each
peptide identified, a minimum MASCOT score that corresponded
to P , 0.05 was considered as a prerequisite for peptide valida-
tion. A second consecutive run was performed from the same
sample vial to perform a single MS data collection. This method
ensured that enough time points would be observed for the
quantification of peptides via extracted ion chromatograms (XICs).
Identification of bioactive peptides
A search for the biological activity of peptides identified was
conducted through the Dziuba database (http://www.uwm.edu.pl/
biochemia/biopep/start_biopep.php) and by comparing sequences
either reviewed or described in numerous articles (19–36).
Quantification of some bioactive peptides
Synthetic peptides were solubilized at 5 g/L in 35 mmol HEPES-
tris buffer/L, which was diluted first 1:1000 with 0.1% TFA
to obtain the 5-mg/L solution. An 8-point calibration was car-
ried out with solutions of b-casein (60–66) (10–1000 pg) and
b-casein (108–113) (10–5000 pg). Quantification was per-
formed using the Analyst QS 1.1 software. Peptide quantity was
measured from the XIC obtained for each peptide. m/z ranges of
790.4 6 0.3 Thomson and 748.39 6 0.3 Thomson were ex-
tracted for b-casein (57–, 58–, 59–, and 60–66) and b-casein
(108–113), respectively. The peak maximum intensities were
considered to construct the calibration curve. The b-casein (60–
66) and b-casein (108–113) quantity (x) in jejunal effluent was
calculated by using the equation
y ¼ bxþ c ð3Þ
where y is the maximal intensity measured on the XIC, c is the
y-axis intercept, and b is the slope of the standard curve of the
peptide. The equations of calibration curves were
y ¼ 14:721xþ 194:94ðR2 ¼ 0:9938Þ ð4Þ
and
y ¼ 3:1187xþ 5:3819ðR2 ¼ 0:999Þ ð5Þ
for b-casein (57–, 58–, 59–, and 60–66) and b-casein (108–
113), respectively. With respect to the quantification of b-casein
(108–113), the XIC of the peptide in most jejunal effluents was
higher than the maximum of our calibration curve; conse-
quently, quantifications were extrapolated from the calibration
curve, which resulted in a potential underestimation of this
peptide quantity.
Calculation of the frequency of the identified peptide
The frequency of a peptide represents the number of times that
it was identified in samples from all subjects fed the same meal
and throughout the digestion. The frequency was calculated as
the ratio of the number of times the peptide was identified over
the number of times the peptide would be identified if present
throughout digestion (12-sample collection for casein and 9-sample
collection forWPs because no peptidewas identified after 5 h) and
for all subjects fed the samemeal (n = 7 for casein; n = 6 forWPs).
Thus, a frequency of 1 meant that the peptide had been identified
in all effluents whatever the digestion time and subject. Peptides
with a frequency $0.60 were named frequent peptides.
Statistics
For nitrogen flow rates, the effect of treatment was assessed by
using a mixed model with the group as a simple factor and time as
a repeated factor with the MIXED procedure in SAS software
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(version 6.11: SAS Institute Inc). P , 0.05 was considered
statistically significant.
RESULTS
Characterization of jejunal effluents
The kinetics of dietary nitrogen flux in the jejunal effluents
differed between casein and WP groups (time 3 group: P ,
0.0001) (Figure 1). The delivery of dietary nitrogen was mas-
sive after WPs and was completed after 3 h, whereas casein-
derived dietary nitrogen was progressively emptied from the
stomach for 6 h postmeal. In contrast, the flux of endogenous
nitrogen remained relatively stable during the kinetic (5–12
mmol N/30 min) and was not different between groups (Figure
1). After 6 h, the jejunal absorption of dietary nitrogen was 626
9% for casein and 50 6 7% for WPs and was, thus, not sig-
nificantly different. The size distribution of peptides detected in
jejunal effluents differed after the ingestion of casein and WPs
(Figure 2). Peptides were classified into 4 groups according to
their molecular weight as follows: 450–750, 750–1050, 1050–1800,
and 1800–3000 Da. For the casein group, most of the peptides
had a molecular weight that ranged from 450 to 1800 Da. The
750–1050-Da peptides (6–9 amino acid residues) were the most
predominant throughout the 6-h digestion, whereas the number
of 1050–1800-Da peptides started to decrease after 3 h of di-
gestion. In the WP group, the predominant frequency of 1050–
1800-Da peptides (9–15 amino acid residues) was observed
throughout the digestion. Almost no peptide was detected 4.5 h
after the meal in this group.
Identification of casein-derived peptides
Within jejunal effluents collected throughout the 6-h digestion,
356 casein-derived peptides were identified including 218 pep-
tides from b-casein (61.2%) and 85 peptides from as1-casein
(24.9%) whereas the other as2- and k-casein–derived peptides
accounted for 8.2% and 6.7%, respectively. For b-casein, no
peptide was shown in the 2 sequences 15–48 and 92–105,
whereas other peptides were recovered in effluent samples from
all subjects that included 11 b-casein–derived peptides with
a frequency .0.60 (see Table S2 under “Supplemental data” in
FIGURE 1. Mean (6SD) contributions of exogenous nitrogen and
endogenous nitrogen to total nitrogen in the jejunum of subjects after the
ingestion of CN or WP (n = 8 per group). Kinetics differed between groups
(mixed-model analysis; time 3 group: P , 0.0001) *Significantly different
at each time point, P , 0.05 (post hoc test). CN, casein; WP, whey proteins.
FIGURE 2. Mean (6SD) numbers of peptides in the jejunum of subjects
after the ingestion of casein (n = 7) and whey proteins (n = 6). Peptides are
classified according to their molecular weight.
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the online issue) with 4 derived from the b-casein (57–68) se-
quence (Figure 3). In addition, 112 peptides were identified
with a frequency ,0.05 (ie, were identified in ,5% of analyzed
samples), in which 12 bioactive peptides were included. The
most-frequent bioactive peptides were b-casomorphins b-casein
(59–66), b-casein (59–68), and b-casein (60–66), the antihyper-
tensive b-casein (108–113) peptide, and other bioactive peptide
precursors including 27 and 32 precursors for the antihypertensive
tripeptides IPP (sequence 74–76) and VPP (sequence 84–86)
(30), respectively. The as1-casein (24–30) peptide was the only
frequent as1-casein–derived peptide (frequency: 0.65), and 45%
of the most frequently identified peptides originated from se-
quence 4–33, which counted many precursors of bioactive pep-
tides (Figure 4). The following 3 bioactive peptides were identified
from as1-casein: as1-casein (24–32) and as1-casein (104–109),
which have an angiotensin-converting enzyme (ACE)–inhibitory
activity, and mineral carrier as1-casein (106–119). Most of the 29
peptides identified from as2-casein were released from the 89–122
sequence, whereas no peptides within the 1–24 sequence were
identified, and only 2 peptides originated from the C-terminal end
of as2-casein. Also, few peptides were identified from the k-casein,
with the most frequent peptides identified from the 52–59 se-
quence. No peptides were identified from the N-terminal end of
k-casein, from the 60–105 sequence, and the C-terminal end. Two
peptides with an antithrombotic activity were shown within the
106–116 sequence.
Identification of WP-derived peptides
Within the jejunal effluents collected from all subjects throughout
the 6-h digestion, 146 peptides originated from WPs, including
105 peptides from b-lactoglobulin (72%), whereas percentages
of peptides identified from a-lactalbumin, bovine serum albumin
(BSA), and lactoferrin represented 15.1%, 11.0%, and 1.4%,
respectively. The 105 peptides identified from b-lactoglobulin
mainly originated from 40–58 and 122–137 sequences, which
seemed to be sequentially hydrolyzed through the action of
peptidases (Figure 5). In contrast, few peptides were shown in
sequences 1–41, 60–82, and 100–121 of b-lactoglobulin. For
a-lactalbumin, 80% of the 85 identified peptides originated from
the 80–90 sequence, and no peptides from the 2 terminal ends
were identified (ie, from 1–17 and 103–123 sequences). For
BSA, 16 peptides were identified. For lactoferrin only, the fol-
lowing 2 peptides were identified: 139–145 and 607–611
FIGURE 3. Milk peptides released from b-casein that were identified by using liquid chromatography–tandem mass spectrometry in jejunal effluents of
humans fed casein (n = 7). Peptides having a biological activity are presented as angiotensin-converting enzyme inhibitory peptides (open bars), opioid
peptides (gray bars), immunomodulary peptides (dotted bar), and antihypertensive peptides (left diagonally hatched bars).
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FIGURE 4. Milk peptides released from as1-, as2-, and k-casein that were identified by using liquid chromatography–tandem mass spectrometry in jejunal
effluents of humans fed casein (n = 7). Peptides having a biological activity are presented as angiotensin-converting enzyme–inhibitory peptides (open bars;
as1-casein), mineral carrier (vertically hatched bar; as1-casein), and antithrombotic peptides (right diagonally hatched bar; k-casein).
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FIGURE 5. Milk peptides released from b-lactoglobulin, a-lactalbumin, and bovine serum albumin that were identified by using liquid chromatography–
tandem mass spectrometry in jejunal effluents of humans fed whey proteins (n = 6).
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sequences. None of the peptides identified from WPs were bio-
active peptides from data reported in the literature (19, 32, 34).
However, peptides identified included 35 precursors of bioactive
peptides from b-lactoglobulin and one a-lactalbumin–derived
(18–20) peptide immunomodulator precursor.
There are some protein sequences for which no peptides were
identified by using our experimental conditions. One possibility is
that these sequences have been degraded in,5 amino acid residue
peptides that were not detectable. Another possibility is that these
peptides were not identified because of their large size.
Quantification of peptides b-casein (57–, 58–, 59–,
and 60–66) and b-casein (108–113)
All b-casein (57–, 58–, 59–, and 60–66) and b-casein (108–
113) bioactive peptides were present in the jejunal effluent
throughout the 6-h digestion (Figure 6). Their amounts tended to
be higher during the first 2 h and decreased thereafter. The
quantity of the b-casein (108–113) peptide was w20-fold higher
than that of the b-casein (60–66) peptide. The cumulated quantity
of the 3 precursors of the b-casein (60–66) peptide and b-casein
(60–66) peptide was calculated. The quantity was the highest at
0.5 h at 3.606 0.35 mg (Figure 6). There was reduction in SD by
cumulated peptides, especially in the first 2 h of digestion, which
suggests that cumulative analyses may be a way to solve diffi-
culties created by the heterogeneity of the digestive process.
After 2 h of digestion, the total quantity of b-casomorphin-7
measured in jejunal effluents was 4 mg. According to the mo-
lecular weight of the peptide (789.4 Da), it was estimated that
.5 mmol were available in a mean volume of jejunal effluent of
3046 12.6 mL (ie, a 17-mmol/L concentration). Similarly, a 40-
mg mean quantity of b-casein (108–113) peptide was measured
in jejunal effluent as early as at 30 min of digestion. According
to the mean volume of jejunal effluent that was 59.7 6 33.2 mL,
it was estimated that 670 mg/mL (equivalent to 0.90 mmol/L)
were available for in vivo activity, which was probably an un-
derestimated quantity.
DISCUSSION
This study aimed to characterize kinetics of the hydrolysis of
milk casein and WPs and identify peptides derived from these
proteins in the jejunal effluent in healthy human subjects. The
results showed that caseins released a wide range of medium-
sized peptides throughout the 6 h of digestion, whereas less
peptides but of larger size were released from WPs. Our work
identified several peptides that have biological activities and also
showed that b-casein (60–66) and (108–113) peptides, which
have opioid and antihypertensive properties, respectively, were
released in amounts that were compatible with a biological action.
Jejunal kinetics of dietary nitrogen are consistent with the
current results on digestion rates of WPs and casein (14, 17, 37).
WPs were entirely emptied from the stomach after 3 h, whereas
caseins were slowly delivered all along the postprandial phase.
However, differences in the gastric emptying rates did not in-
fluence the secretion of the endogenous protein that remained
stable for 6 h and did not increase after the meal. The influence of
dietary proteins on pancreatic secretions has been debated, and
their stimulatory effect remains controversial regarding both
quantitative (38, 39) and qualitative aspects (16, 40), and a mild
stimulation after casein ingestion could not be excluded (15).
The recovery of dietary nitrogen indicated that 50% and 60%
of ingested nitrogen had already been absorbed after 6 h
at the jejunal level in WP and casein groups, respectively. Thus,
the remaining nitrogen compounds were representative of the
less-digestible fraction. An analysis of the degree of hydrolysis of
these compounds showed that, although there was a limited
FIGURE 6. Quantification (means 6 SDs) of bioactive peptides b-CN
(60–66) and (108–113) and the cumulated quantity of b-CN (57–, 58–, 59–,
and 60–66) as measured in jejunal effluents of humans fed casein (n = 7).
CN, casein.
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gastric hydrolysis because of their rapid arrival in the jejunal
lumen, WPs were further hydrolyzed by pancreatic and intestinal
proteases, as shown by the presence ofw40 peptides 1 h after the
meal. The 9–15 amino acid residue peptides were the most fre-
quent throughout WP digestion. In contrast, the predominance of
6–9 amino acid residue peptides from casein suggested that
peptides released from casein are more susceptible to hydrolysis
and subsequent absorption than those from WPs. Actually, the
more advanced the casein digestion was, the smaller the peptides
were. The peptide-length distribution was similar to that obtained
in the duodenum after ingestion of milk or yogurt in humans
(10) and beef meat and trout flesh in pigs (8). Also, large peptides
were sequentially sliced both to N- and C-terminal ends probably
because of the action of carboxypeptidases and aminopeptidases
The absence of the later in pancreatic juice (41, 42) has led to
a consideration of the action of the 6 putative aminopeptidases of
the brush border membrane of epithelial cells (43). These ami-
nopeptidases are located at the surface of the epithelial cells and
can be present in gastrointestinal juice that arise from sloughed-
off mucosal cells (43).
Peptides present in the jejunum throughout digestion were
analyzed in terms of origin and sequence. The large number of
peptides identified from b- and as1-casein covered almost the
whole sequence of both proteins. Few peptides from minor
proteins such as k-casein, lactoferrin, and BSA have been iden-
tified. BSA and lactoferrin are highly structured proteins that
have a molecular weight 5–6 times that of other milk proteins,
which may explain the few peptides identified from both these
proteins. Indeed, lactoferrin was shown to be highly resistant to
gastric digestion in vitro (44) and in adults (45). In addition, scarce
peptides have been identified from sequences b-lactoglobulin
(60–75) and b- lactoglobulin (103–123) that are protected from
digestion by virtue of 4 cysteine residues located at the 66, 106,
119, and 160 amino acid residues that help to maintain the tertiary
structure by forming disulfure bonds. We noticed that most of the
peptides identified (eg, 81% for b-casein peptides) contained $2
proline residues, and the largest peptide identified counted 7
proline residues in sequence on 26 amino acid residues. These
results were in agreement with the generally reported resistance
of proline-containing peptides to gastric and pancreatic digestive
enzymes (28, 46, 47) and epithelial proteases (8). In more detail,
the 3 bonds Pro-Gly (63–64), Gly-Pro (64–65), and Pro-Pro
(75–76; 85–86) were present in most of the peptides identified
throughout digestion. Our results evidenced the predominant
presence of proline-rich peptides and glycine-rich peptides in the
jejunum, which questioned their role in the lumen. Recently,
glycine-rich peptides with an antimicrobial activity have been
reported (48).
Peptides we identified exhibited a wide range of biological
functions, including antihypertensive (such as an ACE inhibitor),
antithrombotic, immunomodulatory, opioid agonist and antago-
nist, and antimicrobial functions. As regards important activities,
b-casomorphins are a family of opioid peptides derived from the
(60–70) of bovine b-casein. In jejunal effluents, we identified 15
opioid sequences that overlaid the common structural motif for
region 60–65 (YPFPGP). These peptides included the well-
known b-casomorphin-7 (60–66) as well as large peptides of 16
amino acid residues such as b-casein (57–72). Previous studies
have shown that b-casomorphin-4 (60–63), b-casomorphin-5 (60–
64), and b-casomorphin-7 are released in the jejunum of minipigs
fed casein (9), and considerable amounts of b-casomorphin-7, but
no b-casomorphin-5, and only small amounts of b-casomorphin-
4 or -6 immunoreactive materials were shown in intestinal ef-
fluents in humans after the ingestion of milk (49). We identified
other numerous precursors of bioactive peptides, particularly the
antihypertensive tripeptides IPP and VPP that cannot be detected
under the conditions used in MS. However, 59 precursors of
both tripeptides have been identified from b-casein.
The frequent identification of b-casomorphin-7 showed that it
was continuously released within the lumen in humans fed casein.
The 17-mmol/L amount estimated after 2 h of digestion was
compatible with an in vivo opioid agonist activity because the half
maximal inhibitory concentration (IC50) of b-casomorphin 7 is 3–
100 mmol/L for this activity (50).
As concerns the antihypertensive activity, the b-casein (108–
113) is an ACE inhibitor that has an IC50 value of 423 mg/mL (31).
The 670-mg/mL concentration estimated after 30 min of digestion
was 1.5 higher than the IC50. The bioavailability of ACE-inhibitor
peptides also depends on their ability to be absorbed to reach
nonluminal targets. It is known that small peptides such as di-
peptides and tripeptides are transported by a specific transporter as
shown for VPP and IPP (51, 52) whereas oligopeptides can be
transported by transcytosis (52, 53) and paracellular routes (52).
Whatever transport mechanism, the intestinal absorption is only 1–
0.1%, which reduces the peptide bioavailability.
In conclusion, the study was conducted in a limited sample size
and in subjects with an invasive method that did not allow large
screening in the population. However, the profiles of hydrolysis
kinetics were very repeatable in subjects and were characteristic
of the protein source. The results prove the in vivo presence of
a wide range of bioactive peptides in jejunal effluents of humans
fed milk proteins. The question arises about the role of these
peptides in the intestinal tract where they may modulate phys-
iologic functions. Additional studies performed on a complex
food matrix, such as milk, should be helpful to understand how
the interaction between proteins affect hydrolysis kinetics.
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